

# Product information



Information about other products is available at: [www.IBL-America.com](http://www.IBL-America.com)

## ImmunoGuide®

### Instructions for Use

## Etanercept ELISA (mAb-based)

Enzyme immunoassay for the specific determination  
of free Etanercept in serum and plasma

REF: TM09006



12X8



2-8°C

**For Research Use Only - Not for Use in Diagnostic Procedures**

Manufactured for  
**Immuno-Biological Laboratories Inc. (IBL-America)**  
8201 Central Avenue NE,  
Suite P Minneapolis,  
MN 55432 USA

Tel: 763-780-2955 Toll Free: 1-888-523-1246

[www.ibl-america.com](http://www.ibl-america.com)

| <b><u>Contents</u></b>                       | <b><u>Page</u></b> |
|--|--------------------|
| 1. Intended Use                              | 2                  |
| 2. Summary and Explanation                   | 2                  |
| 3. Principle of the Test                     | 2                  |
| 4. Warnings and Precautions                  | 3                  |
| 5. Storage and Stability of the Kit          | 3                  |
| 6. Specimen Collection, Handling and Storage | 3                  |
| 7. Contents of the Kit                       | 4                  |
| 8. Materials Required but not Supplied       | 4                  |
| 9. Procedure Notes                           | 5                  |
| 10. Pre-Test Setup Instructions              | 5                  |
| 10.1. Preparation of Components              | 5                  |
| 10.2. Dilution of Standards and Samples      | 6                  |
| 11. Test Procedure                           | 6                  |
| 11.1. General Remarks                        | 6                  |
| 11.2. Assay Procedure                        | 7                  |
| 11.3. Quality Control                        | 8                  |
| 11.4. Calculation of Results                 | 8                  |
| 12. Assay characteristics                    | 9                  |
| 12.1. Specificity                            | 9                  |
| 12.2. Sensitivity                            | 9                  |
| 12.3. Precision                              | 9                  |
| 12.4. Recovery                               | 10                 |
| 13. Automation                               | 10                 |
| 14. References                               | 10                 |

### 1. INTENDED USE

Enzyme immunoassay for the specific determination of free Etanercept in serum and plasma. For research use only - not for use in diagnostic procedures.

### 2. SUMMARY AND EXPLANATION

The drug Etanercept (trade name Enbrel<sup>®</sup>) is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept binds specifically to human tumor necrosis factor alpha (TNF- $\alpha$ ) and blocks its interaction with cell surface TNF receptors. Serum concentration of Etanercept might be related to predict some clinical outcome during maintenance therapy. The specificity of this test system is achieved by using a monoclonal antibody named "5A1 mAb" for the coating of the microtiter plate. This antibody is specific for Etanercept only and does not cross react with other TNF- $\alpha$  catchers.

### 3. PRINCIPLE OF THE TEST

This ELISA is based on Etanercept-specific mouse monoclonal antibody (catcher Ab, *ImmunoGuide* clone 5A1). Diluted standards and samples are incubated in the microtiter plate coated with IG-5A1 mAb. After incubation, the wells are washed. A horseradish peroxidase (HRP)-conjugated anti-human IgG monoclonal antibody is added and binds to the Fc part of Etanercept. Following incubation, wells are washed, and the bound enzymatic activity is detected by addition of chromogen-substrate. The color developed is proportional to the amount of Etanercept in the sample or standard. Results of samples can be determined by using the standard curve. Binding of Etanercept to the solid phase, pre-coated with 5A1, is inhibited by recombinant human TNF- $\alpha$  in a concentration dependent manner. Therefore, the *ImmunoGuide* Etanercept ELISA (mAb-based) measures the free form of Etanercept.

#### 4. WARNINGS AND PRECAUTIONS

1. Before starting the assay, read the instructions completely and carefully. Use the valid version of the package insert provided with the kit. Be sure that everything is understood. For further information (clinical background, test performance, automation protocols, alternative applications, literature, etc.) please refer to the local distributor.
2. In case of severe damage of the kit package, please contact **IBL-America** or your supplier in writing, latest one week after receiving the kit. Do not use damaged components in test runs but keep safe for complaint related issues.
3. Obey lot number and expiry date. Do not mix reagents of different lots. Do not use expired reagents.
4. Follow good laboratory practice and safety guidelines. Wear lab coats, disposable latex gloves and protective glasses where necessary.
5. Reagents of this kit containing hazardous material may cause eye and skin irritations. See MATERIALS SUPPLIED and labels for details.
6. Chemicals and prepared or used reagents have to be treated as hazardous waste according the national biohazard safety guidelines or regulations.
7. Avoid contact with Stop solution. It may cause skin irritations and burns.
8. If any component of this kit contains human serum or plasma it is indicated and if so, it has been tested and were found to be negative for HIV I/II, HBsAg and HCV. However, the presence of these or other infectious agents cannot be excluded absolutely and therefore reagents should be treated as potential biohazards in use and for disposal.
9. Some reagents contain preservatives. In case of contact with eyes or skin, flush immediately with water.

#### 5. STORAGE AND STABILITY OF THE KIT

The kit is shipped at ambient temperature and should be stored at 2-8°C. Keep away from heat or direct sun light. The storage and stability of specimen and prepared reagents is stated in the corresponding chapters. The microtiter strips are stable up to the expiry date of the kit in the broken, but tightly closed bag when stored at 2-8°C.

#### 6. SPECIMEN COLLECTION, HANDLING AND STORAGE

##### Serum, Plasma (EDTA, Heparin)

The usual precautions for venipuncture should be observed. It is important to preserve the chemical integrity of a blood specimen from the moment it is collected until it is assayed. Do not use grossly hemolytic, icteric or grossly lipemic specimens. Samples appearing turbid should be centrifuged before testing to remove any particulate material.

|            |       |                   |  |
|------------|-------|-------------------|--|
| Storage:   | 2-8°C | ≤-20°C (Aliquots) | Keep away from heat or direct sun light<br>Avoid repeated freeze-thaw cycles |
| Stability: | 3 d   | 6 mon             |  |

## 7. CONTENTS OF THE KIT

| QUANTITY   | COMPONENT   |
|------------|---|
| 1 x 12 x 8 | <b>Microtiter ELISA Plate</b><br>Break apart strips coated with anti-Etanercept monoclonal antibody.  |
| 5 x 0.5 mL | <b>Etanercept Standards A-E, Concentrate (10X)</b><br>2000; 600; 200; 60; and 0 ng/mL<br>Used for construction of the standard curve. Contains Etanercept, proteins, preservative and stabilizer. |
| 1 x 12 mL  | <b>Assay Buffer</b><br>Blue colored. Ready to use. Contains proteins and preservative.  |
| 1 x 60 mL  | <b>Dilution Buffer, Concentrate (5X)</b><br>Contains orange dye, proteins and preservative.   |
| 1 x 12 mL  | <b>Enzyme Conjugate</b><br>Red colored. Ready to use. Contains horseradish peroxidase(HRP)-conjugated anti-human IgG mouse monoclonal antibody, Proclin <sup>®</sup> and stabilizers.             |
| 1 x 12 mL  | <b>TMB Substrate Solution</b><br>Ready to use. Contains 3,3',5,5'-Tetramethylbenzidine (TMB).   |
| 1 x 12 mL  | <b>Stop Solution</b><br>Ready to use. 1 N Hydrochloric acid (HCl).  |
| 1 x 50 mL  | <b>Wash Buffer, Concentrate (20x)</b><br>Contains buffer, Tween <sup>®</sup> 20 and Kathon <sup>™</sup> .   |
| 2 x 1      | <b>Adhesive Seal</b><br>For sealing microtiter plate during incubation.   |

## 8. MATERIALS REQUIRED BUT NOT SUPPLIED

1. Micropipettes (< 3% CV) and tips to deliver 5-1000  $\mu$ L.
2. Bidistilled or deionised water and calibrated glasswares (e.g. flasks or cylinders).
3. Wash bottle, automated or semi-automated microtiter plate washing system.
4. Microtiter plate reader capable of reading absorbance at 450 nm (reference wavelength at 600-650 nm is optional).
5. Absorbent paper towels, standard laboratory glass or plastic vials, and a timer.

## 9. PROCEDURE NOTES

1. Any improper handling of samples or modification of the test procedure may influence the results. The indicated pipetting volumes, incubation times, temperatures and pre-treatment steps have to be performed strictly according to the instructions. Use calibrated pipettes and devices only.
2. Once the test has been started, all steps should be completed without interruption. Make sure that required reagents, materials and devices are prepared readily at the appropriate time. Allow all reagents and specimens to reach room temperature (20-25 °C) and gently swirl each vial of liquid reagent and sample before use. Mix reagents without foaming.
3. Avoid contamination of reagents, pipettes and wells/tubes. Use new disposable plastic pipette tips for each reagent, standard or specimen. Do not interchange the caps of vials. Always cap not used vials. Do not reuse wells or reagents.
4. Use a pipetting scheme to verify an appropriate plate layout.
5. Incubation time affects results. All wells should be handled in the same order and time sequences. It is recommended to use an 8-channel Micropipettor for pipetting of solutions in all wells.
6. Microplate washing is important. Improperly washed wells will give erroneous results. It is recommended to use a multichannel pipette or an automatic microplate washing system. Do not allow the wells to dry between incubations. Do not scratch coated wells during rinsing and aspiration. Rinse and fill all reagents with care. While rinsing, check that all wells are filled precisely with Wash Buffer, and that there are no residues in the wells.
7. Humidity affects the coated wells. Do not open the pouch until it reaches room temperature. Unused wells should be returned immediately to the resealed pouch including the desiccant.

## 10. PRE-TEST SETUP INSTRUCTIONS

### 10.1. Preparation of Components\*

| Dilute/<br>dissolve | Component       |                 | Diluent            | Relation | Remarks   | Storage | Stability |
|---------------------|-----------------|-----------------|--------------------|----------|---|---------|-----------|
| 10 mL               | Wash Buffer     | up to<br>200 mL | Distilled<br>Water | 1:20     | Warm up at 37°C to<br>dissolve crystals.<br>Mix vigorously. | 2-8 °C  | 4 w       |
| 10 mL               | Dilution Buffer | up to<br>50 mL  | Distilled<br>Water | 1:5      |   | 2-8 °C  | 4 w       |


\* Prepare Wash and Dilution Buffers before starting the assay procedure.

## 10.2. Dilution of Standards and Samples

The dilutions depicted below are examples of how to obtain final dilutions for standards and samples. Standards and samples should be properly diluted as homogenous mixture before starting the assay procedure. It is recommended mixing the standards and samples well to homogenous solution at each dilution step. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

1. 10  $\mu\text{L}$  of standard added to 90  $\mu\text{L}$  of 1X dilution buffer, giving the total volume of 100  $\mu\text{L}$  and a dilution of 1:10.
2. 10  $\mu\text{L}$  of sample added to 490  $\mu\text{L}$  of 1X dilution buffer, giving the total volume of 500  $\mu\text{L}$  and a dilution of 1:50.
3. Samples with a drug concentration above the measuring range should be rated as ">highest standard". The result should not be extrapolated. The sample in question should be further diluted with 1X Dilution Buffer and then retested.

### Standard/Sample Dilution



## 11. TEST PROCEDURE

### 11.1. GENERAL REMARKS

- 11.1.1. Before performing the assay, samples and assay kit should be brought to room temperature (about 30 minutes beforehand) and ensure the homogeneity of the solution.
- 11.1.2. All Standards should be run with each series of unknown samples.
- 11.1.3. Standards should be subject to the same manipulations and incubation times as the samples being tested.
- 11.1.4. All steps of the test should be completed without interruption.
- 11.1.5. Use new disposable plastic pipette tips for each reagent, standard or specimen in order to avoid cross contamination.

11.1.6. The total pipetting time needed for dispensing all samples into the wells should not exceed 5 minutes. If this is difficult to achieve the samples should be pre-dispensed in a separate neutral polypropylene microplate and then transferred into the reaction ELISA plate by a multi channel pipette.

## 11.2. ASSAY PROCEDURE

|     |  |
|-----|--|
| 1.  | Pipette <b>100<math>\mu</math>L</b> of <b>Assay Buffer</b> into each of the wells to be used.  |
| 2.  | <p>Pipette <b>50 <math>\mu</math>L</b> of each <b>1:10 Diluted Standard, and 1:50 Diluted Samples</b> into the respective wells of the microtiter plate. Bubble formation during the pipetting of standards and samples must be avoided.</p> <p><u>Wells</u></p> <p>A1:                    Standard A<br/>           B1:                    Standard B<br/>           C1:                    Standard C<br/>           D1:                    Standard D<br/>           E1:                    Standard E<br/>           F1 and so on:      Samples (Serum/Plasma)</p> |
| 3.  | Cover the plate with adhesive seal. Shake plate carefully by tapping several times. <b>Incubate the plate on a bench top for 60 min at room temperature (RT, 20-25°C).</b>   |
| 4.  | Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate <b>5 X 350 <math>\mu</math>L</b> of <b>Diluted Wash Buffer</b> per well. Remove excess solution by tapping the inverted plate on a paper towel.   |
| 5.  | Pipette <b>100 <math>\mu</math>L</b> of <b>Enzyme Conjugate</b> (HRP-anti human IgG mAb) into each well.   |
| 6.  | Cover plate with adhesive seal. Shake plate carefully by tapping several times. <b>Incubate the plate on a bench top for 30 min</b> at RT.   |
| 7.  | Remove adhesive seal. Aspirate or decant the incubation solution. Wash the plate <b>5 X 350 <math>\mu</math>L</b> of <b>Diluted Wash Buffer</b> per well. Remove excess solution by tapping the inverted plate on a paper towel.   |
| 8.  | Pipette <b>100 <math>\mu</math>L</b> of Ready-to-Use <b>TMB</b> Substrate Solution into each well.   |
| 9.  | <b>Incubate 10 min</b> at RT. Avoid exposure to direct sunlight.   |
| 10. | Stop the substrate reaction by adding <b>100 <math>\mu</math>L</b> of <b>Stop Solution</b> into each well. Briefly mix contents by <u>gently shaking the plate</u> . Color changes from blue to yellow.  |
| 11. | Measure optical density (OD) with a photometer at <b>450 nm</b> (Reference at OD620 nm is optional) within <b>15 min</b> after pipetting the Stop Solution.  |



### 11. 3. QUALITY CONTROL

The test results are only valid if the test has been performed following the instructions. Moreover the user must strictly adhere to the rules of GLP (Good Laboratory Practice) or other applicable standards/laws. All standards/controls must be found within the acceptable ranges as stated above and/or label. If the criteria are not met, the run is not valid and should be repeated. In case of any deviation, the following technical issues should be reviewed: Expiration dates of (prepared) reagents, storage conditions, pipettes, devices, incubation conditions and washing methods.


### 11. 4. CALCULATION OF RESULTS

A standard curve should be constructed using the standard concentration (X-axis) versus the OD450 (or OD450/620) values (Y-axis). This can be done manually using graph paper or with a computer program. Concerning the data regression by computer, it is recommended to primarily use the "4 Parameter Logistic (4PL)" or alternatively the "point-to-point calculation". In case of manual plot there are 2 options: Semilog graph (see Fig. A) or linear graph (see Fig. B). Semilog graph paper is available at <http://www.papersnake.com/logarithmic/semilogarithmic/>. The concentration of the samples can be read from this standard curve as follows. Using the absorbance value for each sample, determine the corresponding concentration of the drug from the standard curve. This value always has to be multiplied by the individual dilution factor (usually 50). If any diluted sample is reading greater than the highest standard, it should be further diluted appropriately with 1X Dilution Buffer and retested. Also this second dilution has to be used for calculation the final result. We are recommending that each laboratory determines the best initial dilution for their samples in order to minimize retesting.

### Typical Calibration Curve

(All steps were performed at 23°C. Just an example. Do not use it for calculation!)

| 1:10 Diluted Standard | A     | B     | C     | D     | E     |
|-----------------------|-------|-------|-------|-------|-------|
| Concentration (ng/mL) | 200   | 60    | 20    | 6     | 0     |
| Mean OD450/620 nm     | 2.990 | 1.184 | 0.475 | 0.164 | 0.063 |



## 12. ASSAY CHARACTERISTICS

### 12.1. SPECIFICITY

There is no cross reaction with any other proteins present in native human serum and no cross reaction was observed with the other therapeutic antibodies including Infliximab, Adalimumab and Golimumab tested at concentrations up to 500 µg/mL.

### 12.2. SENSITIVITY

The lowest detectable level that can be clearly distinguished from the zero standard is 5 ng/mL (zero standard +2SD read from the curve) under the above-described conditions. Analytical sensitivity is 5 ng/mL, and corresponding to the detection limit (limit of quantification) of 0.25 µg/mL for undiluted clinical samples because the serum or plasma samples are instructed to be diluted at 1:50 before starting the assay

### 12.3. PRECISION

**Intra-assay CV:** <10%.

**Inter-assay CV:** <10%.

#### 12.4. RECOVERY

Recovery rate was found to be >95% with native serum and plasma samples when spiked with exogenous Etanercept.

#### 13. AUTOMATION

The *ImmunoGuide* Etanercept ELISA (mAb-based) is suitable also for being used by an automated ELISA processor.

#### 14. REFERENCES

1. Cheong CU, Chang CP, Chao CM, Cheng BC, Yang CZ, Chio CC. Etanercept attenuates traumatic brain injury in rats by reducing brain TNF-  $\alpha$  contents and by stimulating newly formed neurogenesis. *Mediators Inflamm.* 2013;2013:620837. doi: 10.1155/2013/620837.
2. Jung YS, Park W, Na K. Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis. *J Control Release.* 2013 Oct 28;171(2):143-51.
3. Erdemli Ö, Özen S, Keskin D, Usanmaz A, Batu ED, Atilla B, Tezcaner A. In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes. *J Biomater Appl.* 2014 Oct;29(4):524-42.
4. Chen DY, Chen YM. Response to: 'Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study' by Sanmarti et al. *Ann Rheum Dis.* 2015;74(8):e43. doi: 10.1136/annrheumdis-2015-207543.
5. Jani M, Chinoy H, Warren RB, Griffiths CE, Plant D, Fu B, Morgan AW, Wilson AG, Isaacs JD, Hyrich K, Barton A; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Collaborators. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. *Arthritis Rheumatol.* 2015 May;67(8):2011-9
6. Kneepkens EL, Krieckaert CL, van der Kleij D, Nurmohamed MT, van der Horst-Bruinsma IE, Rispens T, Wolbink GJ. Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. *Ann Rheum Dis.* 2015 Oct;74(10):1825-9.
7. Chen DY, Chen YM, Tsai WC, Tseng JC, Chen YH, Hsieh CW, Hung WT, Lan JL. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. *Ann Rheum Dis.* 2015 Mar;74(3):e16. doi: 10.1136/annrheumdis-2013-203893.
8. Garcês S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. *Ann Rheum Dis.* 2014 Jun;73(6):1138-43.

9. Mahil SK, Arkir Z, Richards G, Lewis CM, Barker JN, Smith CH. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. *Br J Dermatol*. 2013 Aug;169(2):306-13.
10. Sivamani RK, Goodarzi H, Garcia MS, Raychaudhuri SP, Wehrli LN, Ono Y, Maverakis E. Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring. *Clin Rev Allergy Immunol*. 2013;44(2):121-40.
11. Hutmacher MM, Nestorov I, Ludden T, Zitnik R, Banfield C. Modeling the exposure-response relationship of etanercept in the treatment of patients with chronic moderate to severe plaque psoriasis. *J Clin Pharmacol*. 2007;47(2):238-48.
12. Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC, Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. *J Clin Pharmacol*. 2005 Mar;45(3):246-56.
13. Andrick BJ, Schwab AI, Cauley B, O'Donnell LA, Meng WS. Predicting Hemagglutinin MHC-II Ligand Analogues in Anti-TNF $\alpha$  Biologics: Implications for Immunogenicity of Pharmaceutical Proteins. *PLoS One*. 2015 Aug 13;10(8):e0135451. doi: 10.1371/journal.pone.0135451
14. Emery P, Vencovsky J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, Tseluyko V, Zhdan VM, Stasiuk B, Milasiene R, Barrera Rodriguez AA, Cheong SY, Ghil J. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. *Ann Rheum Dis*. 2015 Jul 6. pii: annrheumdis-2015-207588. doi: 10.1136/annrheumdis-2015-207588.
15. Arstikyte I, Kapleryte G, Butrimiene I, Venalis A. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF  $\alpha$  Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. *Biomed Res Int*. 2015;2015:604872. doi: 10.1155/2015/604872.
16. Baldo BA. Chimeric fusion proteins used for therapy: indications, mechanisms, and safety. *Drug Saf*. 2015;38(5):455-79.
17. Deehan M, Garcês S, Kramer D, Baker MP, Rat D, Roettger Y, Kromminga A. Managing unwanted immunogenicity of biologicals. *Autoimmun Rev*. 2015;14(7):569-74.
18. Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, Salas-Heredia E, Sánchez-Barrioluengo M, Barber X, Rosas J; AIRE-MB group. Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. *Patient Prefer Adherence*. 2013;7:961-72.
19. Hunt L, Emery P. Etanercept in the treatment of rheumatoid arthritis. *Expert Opin Biol Ther*. 2013;13(10):1441-50.
20. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, Dijkmans BA, Aarden L, Wolbink GJ. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. *Ann Rheum Dis*. 2011;70(2):284-8.